Annual Review |Dr. Haitao Zhao: Molecular Characteristics, Diagnosis and Treatment, and New Drug Progress and Exploration Prospects in Biliary Tract Cancer

Annual Review |Dr. Haitao Zhao: Molecular Characteristics, Diagnosis and Treatment, and New Drug Progress and Exploration Prospects in Biliary Tract Cancer

Editor's Note: Although biliary tract cancer (BTC) is relatively rare, it has a higher incidence in the Southeast Asian population, with 50% of patients already in advanced stages at diagnosis and a survival period of less than one year. Its impact cannot be ignored. In 2023, China saw the approval and market launch of the first-line immunotherapy for BTC, instilling confidence in clinical treatment and ushering in a new era of research exploration. To shed light on this, our journal invited Dr. Haitao Zhao, Director of the Hepatology Department at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, to review the latest developments in the molecular characteristics, clinical diagnosis and treatment, and new drug research of BTC. He also provides a macroscopic perspective, outlining directions worth exploring, such as precision and personalized treatment. Additionally, he selects three promising treatment clues, aiming to provide important guidance for future clinical practice and research exploration.

Annual Review | Dr. Guiqiang Wang: Pursuing Clinical Cure for Hepatitis B, Focusing on Advances in New Drug Development

Antiviral therapy is the primary treatment strategy for chronic hepatitis B (CHB), aiming to inhibit HBV replication, alleviate liver cell inflammation and fibrosis, and reduce the risk of liver failure, decompensated cirrhosis, and hepatocellular carcinoma (HCC). However, there is currently no treatment that can completely clear covalently closed circular DNA (cccDNA) in infected liver cells, which is a major obstacle to achieving clinical cure for CHB. In recent years, with the continuous development and clinical trials of new drugs targeting different points, exploration of new treatment strategies for the clinical cure of CHB is gradually progressing. To this end, this journal invited Dr. Guiqiang Wang from the Department of Infectious Diseases at Peking University First Hospital to share the latest developments in the field of new drug development for the clinical cure of CHB over the past year.
Anticoagulant Therapy for Acute Pancreatitis-Related Splanchnic Vein Thrombosis

Anticoagulant Therapy for Acute Pancreatitis-Related Splanchnic Vein Thrombosis

The "Hepatology Digest - Liver Vascular Disease Column" is an academic column initiated by Dr. Qixing Shun from the Department of Gastroenterology, Northern Theater General Hospital, in response to the invitation of the editorial department of "Hepatology Digest". It regularly collects and organizes research progress in the field of hepatic vascular diseases. Every two weeks (Wednesday), an important literature is selected for in-depth discussion, aiming to help readers understand the rationale behind clinical research, inspiring clinical and scientific thinking.
Revolutionizing Multiple Myeloma Treatment: FCRL5-Directed CAR-T Cells Enhanced with IL-15 Show Promising Antitumor Activity

Revolutionizing Multiple Myeloma Treatment: FCRL5-Directed CAR-T Cells Enhanced with IL-15 Show Promising Antitumor Activity

In January 2024, a study led by Professor Ting Niu from West China Hospital, Sichuan University was published in the international academic journal ——Signal Transduction And Targeted Therapy (IF=38.104). The title of the study is "Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma". This study sheds light on the promising potential of FCRL5-directed CAR-T cell therapy in the treatment of multiple myeloma (MM).